future glp-1 drugs Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Market Overview: GLP-1 Agonists and

In a phase 2 trial, people with T2D and overweight/obesity achieved greater mean WL with cagrisema 2.4 mg compared to cagrilintide 2.4 mg or semaglutide 2.4 mg alone after 32 weeks of treatment (15.6% WL vs

There is currently no official link or approved indication for using GLP-1 receptor agonists specifically to treat Hashimoto's thyroiditis or its symptoms

Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes

Finally, the role of GLP-1 in CSF secretion was overviewed because recent literature points to its clinical employment in treating IIH

J., John Mann J., et al

EBGM, empirical Bayesian geometric mean